治疗肠易激综合征患者中的脆弱双核阿米巴。
Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome.
机构信息
Department of Medicine, Køge Hospital, Lykkebækvej 1, Køge, Denmark.
出版信息
Am J Trop Med Hyg. 2012 Dec;87(6):1046-52. doi: 10.4269/ajtmh.2012.11-0761. Epub 2012 Oct 22.
Abstract
The role of Dientamoeba fragilis in irritable bowel syndrome (IBS) is incompletely known. We aimed to investigate whether eradication of D. fragilis alleviates symptoms in IBS. Twenty-five D. fragilis-positive IBS patients were treated with Metronidazole (MZ) or Tetracycline. The patients were mostly female (89%), and mean age (SD) was 35.1 (8.2) years. Microbiological response, evaluated 2 weeks post-treatment, was observed in 15 of 25 patients (60%), all by MZ. Clinical response, defined as adequate relief of symptoms, was observed in 7 of 22 patients (32%), all by MZ. In a logistic regression analysis, we found no significant association between clinical and microbiological response. This case study did not support our hypothesis of a simple association between D. fragilis and IBS. Some D. fragilis-infections were insufficiently treated by MZ. Further studies into the prevalence and effect of eradication of D. fragilis in IBS and into efficient treatments of D. fragilis are warranted.
摘要
脆弱双核阿米巴（Dientamoeba fragilis）在肠易激综合征（IBS）中的作用尚不完全清楚。我们旨在研究是否消除脆弱双核阿米巴能缓解 IBS 的症状。25 例脆弱双核阿米巴阳性的 IBS 患者接受甲硝唑（MZ）或四环素治疗。这些患者大多为女性（89%），平均年龄（标准差）为 35.1（8.2）岁。25 例患者中有 15 例（60%）在治疗后 2 周进行了微生物学反应评估，均为 MZ 治疗。22 例患者中有 7 例（32%）定义为症状得到充分缓解的临床反应，均为 MZ 治疗。在逻辑回归分析中，我们未发现微生物学和临床反应之间存在显著关联。这项病例研究不支持我们关于脆弱双核阿米巴与 IBS 之间存在简单关联的假设。一些脆弱双核阿米巴感染用 MZ 治疗不够充分。需要进一步研究脆弱双核阿米巴在 IBS 中的流行程度和消除效果，以及有效治疗脆弱双核阿米巴的方法。
相似文献
1
Treatment of Dientamoeba fragilis in patients with irritable bowel syndrome.治疗肠易激综合征患者中的脆弱双核阿米巴。
Am J Trop Med Hyg. 2012 Dec;87(6):1046-52. doi: 10.4269/ajtmh.2012.11-0761. Epub 2012 Oct 22.
2
Blastocystis hominis and Dientamoeba fragilis in patients fulfilling irritable bowel syndrome criteria.人芽囊原虫和脆弱双核阿米巴在符合肠易激综合征标准的患者中。
Parasitol Res. 2010 Aug;107(3):679-84. doi: 10.1007/s00436-010-1918-7. Epub 2010 Jun 8.
3
Dientamoeba fragilis: initial evidence of pathogenicity in the western lowland gorilla (Gorilla gorilla gorilla).脆弱双核阿米巴：西部低地大猩猩（Gorilla gorilla gorilla）致病性的初步证据。
J Zoo Wildl Med. 2010 Jun;41(2):350-2. doi: 10.1638/2009-0190.1.
4
[Role of Dientamoeba fragilis and Blastocystis spp. in Irritable Bowel Syndrome].[脆弱双核阿米巴和芽囊原虫在肠易激综合征中的作用]
Turkiye Parazitol Derg. 2013;37(2):73-7. doi: 10.5152/tpd.2013.19.
5
The role of Blastocystis sp. and Dientamoeba fragilis in irritable bowel syndrome: a systematic review and meta-analysis.人芽囊原虫和脆弱双核阿米巴在肠易激综合征中的作用：一项系统评价和荟萃分析。
Parasitol Res. 2017 Sep;116(9):2361-2371. doi: 10.1007/s00436-017-5535-6. Epub 2017 Jul 1.
6
Investigation of Dientamoeba fragilis and Blastocystis in patients from Turkey with ulcerative colitis and irritable bowel syndrome: Any relation with genotypes?土耳其溃疡性结肠炎和肠易激综合征患者中脆弱双核阿米巴和芽囊原虫的调查：与基因型有关吗？
Acta Trop. 2022 Jul;231:106451. doi: 10.1016/j.actatropica.2022.106451. Epub 2022 Apr 4.
7
Paromomycin is superior to metronidazole in Dientamoeba fragilis treatment.巴龙霉素优于甲硝唑治疗脆弱双核阿米巴。
Int J Parasitol Drugs Drug Resist. 2019 Dec;11:95-100. doi: 10.1016/j.ijpddr.2019.10.005. Epub 2019 Nov 11.
8
Dientamoeba fragilis and chronic abdominal pain in children: a case-control study.脆弱双核阿米巴与儿童慢性腹痛：病例对照研究。
Arch Dis Child. 2014 Dec;99(12):1109-13. doi: 10.1136/archdischild-2014-305942. Epub 2014 Jul 22.
9
Dientamoeba fragilis, a neglected cause of diarrhea, successfully treated with secnidazole.脆弱双核阿米巴，一种被忽视的腹泻病因，用塞克硝唑成功治愈。
Clin Microbiol Infect. 2003 Feb;9(2):110-3. doi: 10.1046/j.1469-0691.2003.00504.x.
10
The prevalence of intestinal parasites is not greater among individuals with irritable bowel syndrome: a population-based case-control study.肠寄生虫病的流行率在肠易激综合征患者中并不更高：一项基于人群的病例对照研究。
Clin Gastroenterol Hepatol. 2015 Mar;13(3):507-513.e2. doi: 10.1016/j.cgh.2014.07.065. Epub 2014 Sep 16.
引用本文的文献
1
2
A Cross-Sectional Study on the Occurrence of the Intestinal Protist, , in the Gut-Healthy Volunteers and Their Animals.一项关于肠道原生动物 在肠道健康志愿者及其动物中的发生情况的横断面研究。
Int J Mol Sci. 2022 Dec 6;23(23):15407. doi: 10.3390/ijms232315407.
3
Gut Microbiota Shifting in Irritable Bowel Syndrome: The Mysterious Role of sp.肠易激综合征中肠道微生物群的变化：[某种菌]的神秘作用
Front Med (Lausanne). 2022 Jun 20;9:890127. doi: 10.3389/fmed.2022.890127. eCollection 2022.
4
Paromomycin is superior to metronidazole in Dientamoeba fragilis treatment.巴龙霉素优于甲硝唑治疗脆弱双核阿米巴。
Int J Parasitol Drugs Drug Resist. 2019 Dec;11:95-100. doi: 10.1016/j.ijpddr.2019.10.005. Epub 2019 Nov 11.
5
Distribution and relevance of Dientamoeba fragilis and Blastocystis species in gastroenteritis: results from a case-control study.脆弱双核阿米巴和肠内芽囊原虫在肠胃炎中的分布和关联性：一项病例对照研究的结果。
Eur J Clin Microbiol Infect Dis. 2020 Jan;39(1):197-203. doi: 10.1007/s10096-019-03710-z. Epub 2019 Oct 28.
6
No association between abdominal pain and in Dutch and Belgian children.荷兰和比利时儿童腹痛与 无关联。
Arch Dis Child. 2019 Jul;104(7):686-689. doi: 10.1136/archdischild-2018-316383. Epub 2019 Feb 23.
7
The Human Gut Colonizer Respires Using Complex II and Alternative Oxidase to Buffer Transient Oxygen Fluctuations in the Gut.人体肠道定植菌利用复合物 II 和替代氧化酶来缓冲肠道内短暂的氧波动。
Front Cell Infect Microbiol. 2018 Oct 22;8:371. doi: 10.3389/fcimb.2018.00371. eCollection 2018.
8
Clinical and Epidemiological Characteristics of Patients with Infection.感染患者的临床和流行病学特征。
Am J Trop Med Hyg. 2018 Nov;99(5):1170-1173. doi: 10.4269/ajtmh.18-0433.
9
A Mexican Honeymoon Marred by Gastrointestinal Upset: A Case of Dientamoeba fragilis Causing Post-infectious Irritable Bowel Syndrome.一场因胃肠道不适而受损的墨西哥蜜月之旅：一例脆弱双核阿米巴引发感染后肠易激综合征的病例。
Cureus. 2017 Dec 27;9(12):e1992. doi: 10.7759/cureus.1992.
10
The role of Blastocystis sp. and Dientamoeba fragilis in irritable bowel syndrome: a systematic review and meta-analysis.人芽囊原虫和脆弱双核阿米巴在肠易激综合征中的作用：一项系统评价和荟萃分析。
Parasitol Res. 2017 Sep;116(9):2361-2371. doi: 10.1007/s00436-017-5535-6. Epub 2017 Jul 1.
本文引用的文献
1
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota.一种特定于粪便微生物群的亚型肠易激综合征。
Gut. 2012 Jul;61(7):997-1006. doi: 10.1136/gutjnl-2011-301501. Epub 2011 Dec 16.
2
The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.利福昔明治疗肠易激综合征的疗效和安全性：系统评价和荟萃分析。
Am J Gastroenterol. 2012 Jan;107(1):28-35; quiz 36. doi: 10.1038/ajg.2011.355. Epub 2011 Nov 1.
3
In vitro susceptibility testing of Dientamoeba fragilis.脆弱双核阿米巴（Dientamoeba fragilis）的体外药敏试验。
Antimicrob Agents Chemother. 2012 Jan;56(1):487-94. doi: 10.1128/AAC.05125-11. Epub 2011 Oct 24.
4
Blastocystis infection is associated with irritable bowel syndrome in a Mexican patient population.囊胚菌感染与墨西哥患者人群中的肠易激综合征有关。
Parasitol Res. 2012 Mar;110(3):1269-75. doi: 10.1007/s00436-011-2626-7. Epub 2011 Aug 26.
5
Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome.对肠易激综合征患者粪便样本中的微生物群特征进行全球和深入的分子分析。
Gastroenterology. 2011 Nov;141(5):1792-801. doi: 10.1053/j.gastro.2011.07.043. Epub 2011 Aug 5.
6
A review of Dientamoeba fragilis carriage in humans: several reasons why this organism should be considered in the diagnosis of gastrointestinal illness.脆弱双核阿米巴感染的研究进展：该生物体在胃肠道疾病诊断中应被考虑的若干原因。
Gut Microbes. 2011 Jan-Feb;2(1):3-12. doi: 10.4161/gmic.2.1.14755.
7
Post-infectious irritable bowel syndrome: the past, the present and the future.感染后肠易激综合征：过去、现在和未来。
J Gastroenterol Hepatol. 2011 Apr;26 Suppl 3:94-101. doi: 10.1111/j.1440-1746.2011.06643.x.
8
The effect of irritable bowel syndrome on health-related quality of life and health care expenditures.肠易激综合征对健康相关生活质量和医疗支出的影响。
Gastroenterol Clin North Am. 2011 Mar;40(1):11-9. doi: 10.1016/j.gtc.2010.12.013.
9
Epidemiology of IBS.IBS 的流行病学。
Gastroenterol Clin North Am. 2011 Mar;40(1):1-10. doi: 10.1016/j.gtc.2010.12.006.
10
Rifaximin therapy for patients with irritable bowel syndrome without constipation.利福昔明治疗无便秘型肠易激综合征患者。
N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.
Zotero 插件